Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer

Abstract excerpt

BACKGROUND: Tumor mutation burden (TMB), DNA mismatch repair deficiency (dMMR), microsatellite instability (MSI), and PD-L1 amplification (PD-L1 AMP) may predict the efficacy of the PD-1/PD-L1 blockade. With the broadening landscape of immunotherapy use, it is important to identify patients who are likely to benefit from the therapy. This study aimed to characterize the distributions of these biomarkers and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Genetic factors in colorectal cancer
• Share to Lung Cancer Treatments and Mutations